Kazia Therapeutics Ltd
F:NV9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of Kazia Therapeutics Ltd (NV9) under the Base Case is EUR per share. Compared with the current market price of 0.7 EUR, the stock appears .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Our estimate of what one share is worth.
Create a free account · No card needed
Do our valuations actually work? See backtest results .
Intrinsic value next to the price over the past 3 years, and what happened after valuations like today’s.
Create a free account · No card needed
Fundamental Analysis
What Kazia Therapeutics Does
Kazia Therapeutics Ltd. engages in the development of pharmaceutical drug. The company is headquartered in Sydney, New South Wales. The firm collaborates with clinicians, scientists, and researchers across the world for the development of cancer treatment. The Company’s product candidates include Paxalisib and EVT801. Paxalisib (GDC-0084) is invented by Genentech, Inc (South San Francisco, CA). Genentech, Inc is a developer of new cancer medicines across the world.
- Headquarters
- Australia AU
- IPO date
- Sep 1, 1994
Earnings Waterfall
Kazia Therapeutics Ltd
What is the Intrinsic Value of one NV9 stock?
The intrinsic value for Kazia Therapeutics Ltd (NV9) under the Base Case is EUR.
Is NV9 stock undervalued or overvalued?
Compared with the current market price of 0.7 EUR, the stock appears .